Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Arqule, Inc. (NQ: ARQL)
2.800 USD  +0.020 (+0.72%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Arqule, Inc.
 
< Previous 1 2 3 4 5 6 7 Next >
Free Research Reports on ARQL, FIO, SODA and WFM Issued by the Bedford Report
May 09, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
ArQule Reports First Quarter 2013 Financial Results
May 08, 2013
from Business Wire News Releases
First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus’ Board at the 2013 Annual Meeting
May 01, 2013
from Business Wire News Releases
First Manhattan Comments on Addition to Vivus’ Board of Directors
May 01, 2013
from Business Wire News Releases
ArQule to Report First Quarter 2013 Financial Results on May 8, 2013
May 01, 2013
from Business Wire News Releases
ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference
April 23, 2013
from Business Wire News Releases
ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Trial
April 09, 2013
from Business Wire News Releases
ArQule Regains Worldwide Rights to AKT Program
April 01, 2013
from Business Wire News Releases
Programs by the FDA Designed to Speed Up Approval Process for Critical Drugs a Key Factor in Biotech's Industry Success
March 18, 2013
Five Star Equities Provides Stock Research on ArQule and Vanda Pharmaceuticals Read More
from Marketwired News Releases
ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results
March 14, 2013
from Business Wire News Releases
ArQule to Report Fiscal 2012 Financial Results on March 14, 2013
March 07, 2013
from Business Wire News Releases
ArQule, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
February 27, 2013
from Business Wire News Releases
ArQule, Inc. to Present at RBC Capital Markets Global Healthcare Conference
February 19, 2013
from Business Wire News Releases
Biotechnology Industry Soars in 2012 as FDA Drug Approvals at a 15-Year High
February 13, 2013
Research Driven Investing Provides Stocks Research on ArQule and BioCryst Pharmaceuticals Read More
from Marketwired News Releases
ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference
February 07, 2013
from Business Wire News Releases
Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib
January 31, 2013
from Business Wire News Releases
Free Research Reports on ARQL, BBY, CATM and DNDN Issued by the Bedford Report
January 14, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer
January 11, 2013
from Business Wire News Releases
ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087, an FGFR Inhibitor
December 13, 2012
from Business Wire News Releases
ArQule, Inc. to Present at Oppenheimer Healthcare Conference
December 05, 2012
from Business Wire News Releases
Edison expands oncology sector presence with launch of coverage of ArQule
November 27, 2012
from Business Wire News Releases
ArQule, Inc. to Present at Lazard Healthcare Conference
November 07, 2012
from Business Wire News Releases
ArQule Announces Third Quarter Fiscal 2012 Results
November 01, 2012
from Business Wire News Releases
ArQule to Report Third Quarter 2012 Financial Results on November 1, 2012
October 25, 2012
from Business Wire News Releases
ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma
October 16, 2012
from Business Wire News Releases
Insider Hot Stocks: Sprint Nextel, ArQule, Illumina, Alpha Natural Resources, Coca-Cola, and Host Hotels and Resorts
October 03, 2012
from PR Newswire
ArQule and Daiichi Sankyo Announce Discontinuation of Phase 3 MARQUEE Clinical Trial in Non-Small Cell Lung Cancer
October 02, 2012
from Business Wire News Releases
ArQule, Inc. to Present at UBS Global Life Sciences Conference
September 12, 2012
from Business Wire News Releases
ArQule, Inc. to Present at Upcoming Investment Conferences
August 30, 2012
from Business Wire News Releases
ArQule Reports Second Quarter 2012 Financial Results
August 02, 2012
from Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here